Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Target Price at $8.67

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average rating of “Moderate Buy” by the five research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.6667.

Several brokerages recently weighed in on PYXS. Zacks Research raised Pyxis Oncology from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Wall Street Zen raised Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 24th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a research report on Tuesday, August 19th.

Pyxis Oncology Trading Up 10.5%

Shares of PYXS opened at $1.47 on Friday. The firm has a market cap of $91.17 million, a PE ratio of -0.92 and a beta of 1.14. The company’s 50 day simple moving average is $1.18 and its 200-day simple moving average is $1.15. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The company had revenue of $2.82 million for the quarter. As a group, equities research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in shares of Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares in the last quarter. Barclays PLC raised its stake in shares of Pyxis Oncology by 20.2% during the 4th quarter. Barclays PLC now owns 77,013 shares of the company’s stock worth $121,000 after buying an additional 12,924 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Pyxis Oncology during the 4th quarter worth $26,000. Jane Street Group LLC raised its stake in shares of Pyxis Oncology by 36.6% during the 4th quarter. Jane Street Group LLC now owns 67,686 shares of the company’s stock worth $106,000 after buying an additional 18,128 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of Pyxis Oncology during the 4th quarter worth $35,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.